Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...

Nearly half of BioSpace poll respondents recently took a biopharma job they were overqualified for, a finding that didn’t ...

A group of medical experts expressed concern about growing "disinformation" and "misinformation," calling for adherence to ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Democratic senators from Georgia, Oregon, Maryland and New Mexico called the Trump administration’s decision to terminate ...

The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...